ALNA
Income statement / Annual
Last year (2021), Allena Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2021, Allena Pharmaceuticals, Inc.'s net income was -$33.36 M.
See Allena Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$20.38 M
|
$20.38 M
|
$37.24 M
|
$26.38 M
|
$15.52 M
|
$20.10 M
|
$11.54 M
|
| General & Administrative Expenses |
$11.60 M
|
$11.60 M
|
$9.68 M
|
$8.64 M
|
$5.43 M
|
$4.08 M
|
$2.37 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$576,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.60 M
|
$11.60 M
|
$9.68 M
|
$9.22 M
|
$5.43 M
|
$4.08 M
|
$2.37 M
|
| Other Expenses |
$0.00
|
$0.00
|
$605,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$31.99 M
|
$31.99 M
|
$46.92 M
|
$35.59 M
|
$20.95 M
|
$24.19 M
|
$13.91 M
|
| Cost And Expenses |
$31.99 M
|
$31.99 M
|
$46.92 M
|
$35.59 M
|
$20.95 M
|
$24.19 M
|
$13.91 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$510,000.00
|
-$510,000.00
|
$270,000.00
|
$575,000.00
|
-$443,000.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$363,000.00
|
$166,000.00
|
$163,000.00
|
$78,000.00
|
$73,000.00
|
$46,000.00
|
$98,000.00
|
| EBITDA |
-$31.97 M |
-$32.68 M |
-$47.18 M |
-$35.57 M |
-$21.58 M |
-$24.46 M |
-$14.15 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$510,000.00
|
-$859,000.00
|
$0.00
|
-$55,000.00
|
-$700,000.00
|
-$321,000.00
|
-$342,000.00
|
| Income Before Tax |
-$32.85 M
|
-$32.85 M
|
-$47.34 M
|
-$35.65 M
|
-$21.65 M
|
-$24.51 M
|
-$14.25 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$510,000.00
|
-$859,000.00
|
-$419,000.00
|
-$55,000.00
|
-$700,000.00
|
-$321,000.00
|
-$342,000.00
|
| Net Income |
-$33.36 M
|
-$32.85 M
|
-$47.34 M
|
-$35.65 M
|
-$21.65 M
|
-$24.51 M
|
-$14.25 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.03 |
-1.01 |
-2.13 |
-1.72 |
-4.79 |
-1.6 |
-0.93 |
| EPS Diluted |
-1.03 |
-1.01 |
-2.13 |
-1.72 |
-4.79 |
-1.6 |
-0.93 |
| Weighted Average Shares Out |
$32.51 M
|
$32.51 M
|
$22.18 M
|
$20.74 M
|
$4.52 M
|
$15.28 M
|
$15.29 M
|
| Weighted Average Shares Out Diluted |
$32.51 M
|
$32.51 M
|
$22.18 M
|
$20.74 M
|
$4.52 M
|
$15.28 M
|
$15.29 M
|
| Link |
|
|
|
|
|
|
|
